medigraphic.com
ISSN 1729-6935 (Electronic)
16 de abril

2021, Number 282

<< Back Next >>

16 de abril 2021; 60 (282)

Influence of genetics and genomics on the treatment with antihypertensive diuretics

Landrove-Escalona EA, Moreira-Díaz LR, Reyes-Ávila MA

Language: Spanish
References: 29
Page: 1-7
PDF size: 468.73 Kb.


ABSTRACT

Introduction: arterial hypertension is considered a worldwide health problem. Several pharmacological studies report adverse effects associated to the influence of genetic and genomic component in antihypertensive drugs, based on the use of the principles of pharmacogenetics and pharmacogenomics.
Objective: to describe the influence of the genetic and genomic component in the treatment with antihypertensive diuretics.
Method: a literature review was conducted from April to May 2021. The available resources in PubMed/MEDLINE and SciELO were used. Of 32 references found using the health sciences descriptors, 29 bibliographic references that met the selection criteria were consulted.
Development: genetic variants that impair drug-receptor interactions or subsequent intracellular signaling can change pharmacodynamics and drug efficacy. The effects of diuretics are made through different mechanisms; several candidate genes have been suggested to influence individual responses to these drugs. Improvements in blood pressure in response to hydrochlorothiazide treatment have been observed in GC genotype carriers compared to CC genotype carriers.
Conclusions: genetic polymorphisms influence the response to diuretic antihypertensives since they intervene in salt sensitivity and plasma renin concentrations. Better antihypertensive responses are evidenced in individuals carrying the AA+AG genotypes compared to GG carriers.


REFERENCES

  1. Slivnick J, Lampert BC.Hypertension and Heart Failure.Heart Fail Clin [Internet]. 2019[cited 04/07/2021]; 15(4):531-541. Available from: https://doi:10.1016/j.hfc.2019.06.007

  2. Tsioufis C, ThomopoulosC. Combination drug treatmentin hypertension. PharmacolRes [Internet]. 2017 [cited04/07/21]; 125(3):266-271. Availablefrom: https://doi:10.1016/j.phrs.2017.09.011

  3. Peacock E, Krousel-WoodM. Adherence to AntihypertensiveTherapy. Med Clin NorthAm [Internet]. 2017 [cited04/07/21];101(1):229-245. Availablefrom: https://doi:10.1016/j.mcna.2016.08.005

  4. Chang TI. Impact of drugson intradialytic hypotension: Antihypertensivesand vasoconstrictors.Semin Dial [Internet].2017 [cited 04/07/21];30(6):532-536. Available from: https://doi:10.1111/sdi.12633

  5. Ormond KE, Mortlock DP,Scholes DT, Bombard Y, BrodyLC, Faucett WA, et al. HumanGermline Genome Editing. Am JHum Genet [Internet]. 2017 [cited04/07/21];101(2):167-176. Availablefrom: https://doi:10.1016/j.ajhg.2017.06.012

  6. Sychev DA, Shih NV, KalleEG, Ryzhikova KA, Morozova TE.Farmakogeneticheskiepodkhodyv prognozirovaniiéffektivnostii bezopasnostiamlodipina ubol’nykharterial’noĭgipertenzieĭ[Pharmacogenetic approachesto predicting the efficiencyand safety of amlodipine in patientswith arterial hypertension].Biomed Khim Russian [Internet].2017 [cited 04/07/21];63(5):432-439. Available from:https://doi:10.18097/PBMC20176305432

  7. Kelley EF, Olson TP, CurryTB, Sprissler R, Snyder EM.The Effect of Genetically GuidedMathematical Predictionand the Blood Pressure Responseto Pharmacotherapy inHypertension Patients. ClinMed Insights Cardiol [Internet].2019 [cited 04/07/21];1 3 : 1 1 7 9 5 4 6 8 1 9 8 4 5 8 8 3 .Available from: https://doi:10.1177/1179546819845883

  8. Oparil S, Acelajado MC,Bakris GL, Berlowitz DR, CífkováR, Dominiczak AF, et al. Hypertension.Nat Rev Dis Primers[Internet]. 2018 [cited 04/07/21];4:18014. Available from: https://doi:10.1038/nrdp.2018.14

  9. Eadon MT, Kanuri SH;Chapman AB.Pharmacogenomicstudies of hypertension: pavingthe way for personalized antihypertensivetreatment. ExpertRevPrecis Med Drug Dev [Internet].2018 [cited 04/07/21];3(1):33-47. Available from:https://doi.org/10.1080/23808993.2018.1420419

  10. Roush GC, Sica DA. Diureticsfor Hypertension: A Reviewand Update. Am J Hypertens [Internet].2016 [cited 04/07/21];29(10):1130-7. Available from:https://doi:10.1093/ajh/hpw030

  11. Singh S, McDonoughCW,Gong Y, AlghamdiWA,ArwoodMJ, BargalSA, et al. Genomewide association study identifiesthe HMGCS2 Locus to be AssociatedWithChlorthalidone InducedGlucose Increase in HypertensivePatients. J Am HeartAssoc [Internet]. 2018 [cited04/07/21]; 7(6) e007339. Availablefrom: http://doi.org/10.1161/JAHA.117.007339

  12. Carey RM, MuntnerP, Bosworth HB, Whelton PK.Prevention and Control ofHypertension: JACC HealthPromotion Series. J Am CollCardiol[Internet]. 2018 [cited04/07/21];72(11):1278-1293. Available from: https://doi:10.1016/j.jacc.2018.07.0084

  13. Eadon MT, Kanuri SH,Chapman AB. Pharmacogenomicstudies of hypertension:paving the way for personalizedantihypertensive treatment. ExpertRev Precis Med Drug Dev[Internet]. 2018 [cited 04/07/21];3(1):33-47. Available from:https://doi:10.1080/23808993.2018.1420419

  14. Surendran P, Drenos F,Young R, Warren H, Cook JP,Manning AK. Trans-ancestry meta-analyses identify rare and commonvariants associated withblood pressure and hypertension.NatGenet [Internet]. 2016[cited 04/07/21];48(10):1151-1161. Available from: https://doi:10.1038/ng.3654

  15. Petrie JR, Guzik TJ, TouyzRM. Diabetes, Hypertension, andCardiovascular Disease: ClinicalInsights and Vascular Mechanisms.Can J Cardiol [Internet].2018 [cited 04/07/21];34(5):575-584. Available from: https://doi:10.1016/j.cjca.2017.12.005

  16. Morrell NW, Aldred MA,Chung WK, Elliott CG, NicholsWC, Soubrier F, et al. Genesalttics and genomics of pulmonaryarterial hypertension.EurRespir J [Internet]. 2019 [cited04/07/21];53(1):1801899.Available from: https://doi:10.1183/13993003.01899-2018

  17. Manosroi W, WilliamsGH. Genetics of Human PrimaryHypertension: Focus on HormonalMechanisms. Endocr Rev[Internet]. 2019 [cited 04/07/21];40(3): 825-856. Available from:ht tps ://doi :10.1210/er.2018-00071

  18. Louca P, Menni C, PadmanabhanS. Genomic Determinantsof Hypertension With aFocus on Metabolomics and theGut Microbiome. Am J Hypertens[Internet]. 2020 [cited04/07/21];33(6):473-481. Availablefrom: https://doi:10.1093/ajh/hpaa022

  19. Williams RB, Bishop GD,Haberstick BC, Smolen A, BrummettBH, Siegler IC, et al. Populationdifferences in associationsof serotonin transporter promoterpolymorphism (5HTTLPR)di- and triallelic genotypes withblood pressure and hypertensionprevalence. Am Heart J [Internet]. 2017 [cited 04/07/21]; 185:110-122. Avilable from: https://doi.org/10.1016/j.ahj.2016.12.013

  20. Magvanjav O, Gong Y,McDonough CW, Chapman AB,Turner ST, Gums JG, et al. Geneticvariants associated withuncontrolled blood pressureon thiazide diuretic/beta-blockercombination therapy in thePEAR (Pharmacogenomic Evaluationof Antihypertensive Responses)and INVEST (InternationalVerapamil-SR TrandolaprilStudy) Trials. J Am HeartAssoc[Internet]. 2017 [cited 04/07/21];6(11): e006522. Available from:ht t p : // d x . doi . o rg / 1 0 . 1 1 6 1 /JAHA.117.006522

  21. Ferdinand KC, Yadav K,NasserSA, Clayton-Jeter HD, LewinJ, Cryer DR, et al. Disparities inhypertension and cardiovasculardisease in blacks: The criticalrole of medication adherence. JClinHypertens (Greenwich) [Internet].2017 [cited 04/07/21];19(10): 1015-1024. Availablefrom: https://doi:10.1111/jch.13089

  22. Sá ACC, Webb A, GongY, McDonough CW, Shahin MH,Datta S, et al. Blood pressuresignature genes and blood pressureresponse to thiazide diuretics:results from the PEARand PEAR-2 studies. BMC MedGenomics [Internet]. 2018 [cited04/07/21];11(1):55. Availablefrom: https://doi:10.1186/s12920-018-0370-x

  23. Tu YA, Lin SJ, Chen PL,Chou CH, Huang CC, Ho HN, etal. HSD3B1 gene polymorphismand female pattern hair loss inwomen with polycystic ovarysyndrome. J Formos Med Assoc[Internet]. 2019 [cited 04/07/21];118(8): 1225-1231. Availablefrom: https://doi:10.1016/j.jfma.2019.04.013

  24. Christian C, Borden BA,Danahey K, Yeo KJ, van WijkXMR, Ratain MJ, et al. Pharmacogenomic-Based DecisionSupportto Predict Adherence toMedications. ClinPharmacolTher[Internet]. 2020 [cited 04/0 7/21];108(2):368-376. Available from:https://doi:10.1002/cpt.1838

  25. Ma H, He Y, Bai M, Zhu L,He X, Wang L, et al. The geneticpolymorphisms of ZC3HC1 andSMARCA4 are associated withhypertension risk. Mol GenetGenomicMed[Internet]. 2019 [cited04/07/21];7(11): e942. Availablefrom: https://doi:10.1002/mgg3.942

  26. Carey RM, Calhoun DA,Bakris GL, Brook RD, DaughertySL, Dennison-HimmelfarbCR, et al. Resistant Hypertension:Detection, Evaluation,and Management: A ScientificStatement From the AmericanHeart Association. Hypertension[Internet]. 2018 [cited04/07/21]; 72(5): e53-e90. Availablefrom: https://doi:10.1161/HYP.0000000000000084

  27. Loganathan L, GopinathK, Sankaranarayanan VM, KukretiR, Rajendran K, Lee JK, et al.Computational and PharmacogenomicInsights on HypertensionTreatment: Rational DrugDesign and Optimization Strategies.Curr Drug Targets [Internet].2020 [cited 04/07/21];21(1):18-33. Available from: https://doi:10.2174/1389450120666190808101356

  28. Oliveira-Paula GH, PereiraSC, Tanus-Santos JE, LacchiniR. Pharmacogenomics AndHypertension: Current Insights.Pharmgenomics Pers Med [Internet].2019 [cited 04/07/21];12:341-359. Available from:h t t p s : // d o i : 1 0 . 2 1 4 7 / P G P M .S230201

  29. Padmanabhan S, DominiczakAF. Genomics of hypertension:the road to precisionmedicine. Nat Rev Cardiol [Internet].2021 [cited 04/07/21];18(4):235-250. Available from:h t t p s : // d o i : 1 0 . 1 0 3 8 / s 4 1 5 6 9 -020-00466-4




2020     |     www.medigraphic.com